• 1
    Ridyard CH, Hughes DA. Methods for the collection of resource use data within clinical trials: a systematic review of trials funded by the UK Health Technology Assessment programme. Value Health 2010;13:In press.
  • 2
    Department of Health and Human Services, Food and Drug Administration. International Conference on Harmonisation: choice of control group in clinical trials. Fed Regist 1999;64:5176780.
  • 3
    Zwarenstein M, Treweek S, Gagnier JJ, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. BMJ 2008;337:18.
  • 4
    Sorenson C, Drummond M, Kanavos P, McGuire A. National Institute for Health and Clinical Excellence (NICE): how does it work and what are the implications for the U.S.? Available from:[Accessed April 2008.
  • 5
    D'Agostino RB Jr, D'Agostino RB Sr. Estimating treatment effects using observational data. JAMA 2007;297:3146.
  • 6
    Harrington RA, Ohman EM. The enigma of drug-eluting stents: hope, hype, humility and advancing patient care. JAMA 2007;297:202830.
  • 7
    McFadden EP, Stabile E, Regar E, et al. Late stent thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:151921.
  • 8
    Spertus JA, Kettellamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from PREMIER registry. Circulation 2006;113:28039.
  • 9
    Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:20019.
  • 10
    Beohar N, Davidson CJ, Kip KE, et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents. JAMA 2007;297:19922000.
  • 11
    Reed SD, Anstrom KJ, Bakhai A, et al. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J 2005;149:43443.